Latest Insider Transactions at Annexon, Inc. (ANNX)
This section provides a real-time view of insider transactions for Annexon, Inc. (ANNX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Annexon, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Annexon, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 30
2024
|
Douglas Love PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
114,449
+16.31%
|
$114,449
$1.85 P/Share
|
|
Oct 15
2024
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
SELL
Open market or private sale
|
Direct |
5,408
-7.04%
|
$37,856
$7.41 P/Share
|
|
Oct 15
2024
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,408
+6.58%
|
$5,408
$1.85 P/Share
|
|
Oct 01
2024
|
William H. Carson |
BUY
Open market or private purchase
|
Direct |
3,200
+12.5%
|
$16,000
$5.97 P/Share
|
|
Sep 19
2024
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
SELL
Open market or private sale
|
Indirect |
4,500
-100.0%
|
$31,500
$7.1 P/Share
|
|
Sep 12
2024
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
SELL
Open market or private sale
|
Indirect |
5,500
-55.0%
|
$33,000
$6.16 P/Share
|
|
Sep 05
2024
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
SELL
Open market or private sale
|
Indirect |
5,500
-35.48%
|
$27,500
$5.64 P/Share
|
|
Sep 03
2024
|
William H. Carson |
BUY
Open market or private purchase
|
Direct |
3,200
+14.29%
|
$16,000
$5.48 P/Share
|
|
Aug 29
2024
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
SELL
Open market or private sale
|
Indirect |
5,500
-26.19%
|
$27,500
$5.95 P/Share
|
|
Aug 01
2024
|
William H. Carson |
BUY
Open market or private purchase
|
Direct |
3,200
+16.67%
|
$19,200
$6.24 P/Share
|
|
Jul 15
2024
|
Michael Overdorf EVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
784
-0.82%
|
$4,704
$6.02 P/Share
|
|
Jul 15
2024
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
SELL
Open market or private sale
|
Direct |
1,106
-1.53%
|
$6,636
$6.02 P/Share
|
|
Jul 15
2024
|
Jennifer Lew EVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,104
-1.26%
|
$6,624
$6.03 P/Share
|
|
Jul 01
2024
|
William H. Carson |
BUY
Open market or private purchase
|
Direct |
3,200
+20.0%
|
$16,000
$5.0 P/Share
|
|
Jun 03
2024
|
William H. Carson |
BUY
Open market or private purchase
|
Direct |
3,200
+25.0%
|
$12,800
$4.83 P/Share
|
|
May 01
2024
|
William H. Carson |
BUY
Open market or private purchase
|
Direct |
3,200
+33.33%
|
$12,800
$4.68 P/Share
|
|
Apr 08
2024
|
William H. Carson |
BUY
Open market or private purchase
|
Direct |
3,200
+50.0%
|
$19,200
$6.07 P/Share
|
|
Feb 20
2024
|
Michael Overdorf EVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,951
-2.23%
|
$9,755
$5.48 P/Share
|
|
Feb 20
2024
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
SELL
Open market or private sale
|
Direct |
2,604
-3.47%
|
$13,020
$5.51 P/Share
|
|
Feb 20
2024
|
Jennifer Lew EVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,593
-3.06%
|
$12,965
$5.53 P/Share
|
|
Feb 16
2024
|
Michael Overdorf EVP & CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
39,000
+30.81%
|
-
|
|
Feb 16
2024
|
Jamie Dananberg CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
39,000
+50.0%
|
-
|
|
Feb 16
2024
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
39,000
+34.19%
|
-
|
|
Feb 16
2024
|
Jennifer Lew EVP & CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
39,000
+31.54%
|
-
|
|
Feb 16
2024
|
Dean Richard Artis EVP & CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
39,000
+30.39%
|
-
|
|
Feb 12
2024
|
Douglas Love PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
5,782
-2.86%
|
$28,910
$5.54 P/Share
|
|
Feb 12
2024
|
Michael Overdorf EVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,349
-2.7%
|
$6,745
$5.53 P/Share
|
|
Feb 12
2024
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
SELL
Open market or private sale
|
Direct |
1,810
-4.78%
|
$9,050
$5.54 P/Share
|
|
Feb 12
2024
|
Jennifer Lew EVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,809
-3.81%
|
$9,045
$5.54 P/Share
|
|
Dec 27
2023
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
SELL
Open market or private sale
|
Direct |
21,000
-100.0%
|
$84,000
$4.52 P/Share
|
|
Dec 27
2023
|
Ted Yednock EVP & CHIEF INNOVATION OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
21,000
+41.54%
|
$21,000
$1.63 P/Share
|
|
Dec 26
2023
|
Muneer A Satter |
BUY
Open market or private purchase
|
Indirect |
350,000
+4.51%
|
$700,000
$2.88 P/Share
|
|
Jul 11
2023
|
Jennifer Lew EVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,057
-2.18%
|
$3,171
$3.84 P/Share
|
|
Jul 11
2023
|
Michael Overdorf EVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
978
-2.09%
|
$2,934
$3.84 P/Share
|
|
May 25
2023
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
300,000
+5.0%
|
$600,000
$2.13 P/Share
|
|
Feb 16
2023
|
Jennifer Lew EVP & CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
18,975
+28.11%
|
-
|
|
Feb 16
2023
|
Michael Overdorf EVP & CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
18,975
+28.86%
|
-
|
|
Feb 15
2023
|
Douglas Love PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
6,571
-3.22%
|
$32,855
$5.87 P/Share
|
|
Feb 14
2023
|
Jennifer Lew EVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
166
-0.56%
|
$996
$6.3 P/Share
|
|
Feb 14
2023
|
Michael Overdorf EVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
144
-0.52%
|
$864
$6.3 P/Share
|
|
Feb 13
2023
|
Jennifer Lew EVP & CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,742
-5.54%
|
$10,452
$6.31 P/Share
|
|
Feb 13
2023
|
Michael Overdorf EVP & CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,501
-5.1%
|
$9,006
$6.3 P/Share
|
|
Feb 10
2023
|
Muneer A Satter |
BUY
Open market or private purchase
|
Indirect |
2,647,058
+27.28%
|
$15,882,348
$6.8 P/Share
|
|
Jul 11
2022
|
Michael Overdorf EVP & CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+30.0%
|
-
|
|
Jul 11
2022
|
Larry Mattheakis EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,376
+21.43%
|
-
|
|
Jul 11
2022
|
Jennifer Lew EVP & CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+28.2%
|
-
|
|
Jul 07
2022
|
Muneer A Satter |
BUY
Open market or private purchase
|
Indirect |
2,453,988
+35.76%
|
$7,361,964
$3.84 P/Share
|
|
Apr 14
2022
|
Douglas Love PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
60,000
+22.99%
|
$120,000
$2.45 P/Share
|
|
Feb 11
2022
|
Larry Mattheakis EVP & Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+50.0%
|
-
|
|
Feb 11
2022
|
Jennifer Lew EVP & CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+46.3%
|
-
|